TY - JOUR
T1 - Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries
T2 - A Time Series Analysis
AU - The RESCEU Investigators
AU - Johannesen, Caroline K.
AU - van Wijhe, Maarten
AU - Tong, Sabine
AU - Fernández, Liliana V.
AU - Heikkinen, Terho
AU - van Boven, Michiel
AU - Wang, Xin
AU - Bøås, Håkon
AU - Li, You
AU - Campbell, Harry
AU - Paget, John
AU - Stona, Luca
AU - Teirlinck, Anne
AU - Lehtonen, Toni
AU - Nohynek, Hanna
AU - Bangert, Mathieu
AU - Fischer, Thea K.
A2 - Nair, Harish
A2 - Beutels, Philippe
A2 - Bont, Louis
A2 - Pollard, Andrew
A2 - Openshaw, Peter
A2 - Martinon-Torres, Federico
A2 - Meijer, Adam
A2 - van den Berge, Maarten
A2 - Giaquinto, Carlo
A2 - Abram, Michael
A2 - Swanson, Kena
A2 - Rizkalla, Bishoy
A2 - Vernhes, Charlotte
A2 - Gallichan, Scott
A2 - Aerssens, Jeroen
A2 - Kumar, Veena
A2 - Molero, Eva
N1 - Funding Information:
Potential conflicts of interest . H. C. reports funding for the submitted work also supported meetings and travel. J. P. reports payments to his institution from Sanofi, AstraZeneca, and Fondation de France for other RSV projects. S. T. and M. B. are employees of Sanofi. T. K. F. reports participating in research funded by Pfizer outside the submitted work. T. H. reports personal fees from Janssen outside the submitted work. Y. L. reports grants from World Health Organization and the Wellcome Trust, outside the submitted work. All other authors report no potential conflicts.
Funding Information:
We thank Ingvild Klundby and Anne-Marte Bakken Kran at the Department of Microbiology, Oslo University Hospital, Ullevål, for providing aggregated laboratory data on RSV infections for the Norwegian team; and the Dutch Working Group for Clinical Virology (NWKV) for providing virus diagnostic data from 20 hospitals and peripheral diagnostic laboratories spread throughout the Netherlands. We acknowledge the support of the eDRIS team (Public Health Scotland) for their involvement in obtaining approvals, provisioning and linking data, and the use of the secure analytical platform within the National Safe Haven. This work was supported by the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 116019). This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations.
Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Background. Knowledge on age-specific hospitalizations associated with RSV infection is limited due to limited testing, especially in older children and adults in whom RSV infections are not expected to be severe. Burden estimates based on RSV coding of hospital admissions are known to underestimate the burden of RSV. We aimed to provide robust and reliable age-specific burden estimates of RSV-associated hospital admissions based on data on respiratory infections from national health registers and laboratory-confirmed cases of RSV. Methods. We conducted multiseason regression analysis of weekly hospitalizations with respiratory infection and weekly laboratory-confirmed cases of RSV and influenza as covariates, based on national health registers and laboratory databases across 6 European countries. The burden of RSV-associated hospitalizations was estimated by age group, clinical diagnosis, and presence of underlying medical conditions. Results. Across the 6 European countries, hospitalizations of children with respiratory infections were clearly associated with RSV, with associated proportions ranging from 28% to 60% in children younger than 3 months and we found substantial proportions of admissions to hospital with respiratory infections associated with RSV in children younger than 3 years. Associated proportions were highest among hospitalizations with ICD-10 codes of “bronchitis and bronchiolitis.” In all 6 countries, annual incidence of RSV-associated hospitalizations was.40 per 1000 persons in the age group 0-2 months. In age group 1-2 years the incidence rate ranged from 1.3 to 10.5 hospitalizations per 1000. Adults older than 85 years had hospitalizations with respiratory infection associated to RSV in all 6 countries although incidence rates were low. Conclusions. Our findings highlight the substantial proportion of RSV infections among hospital admissions across different ages and may help public health professionals and policy makers when planning prevention and control strategies. In addition, our findings provide valuable insights for health care professionals attending to both children and adults presenting with symptoms of viral respiratory infections.
AB - Background. Knowledge on age-specific hospitalizations associated with RSV infection is limited due to limited testing, especially in older children and adults in whom RSV infections are not expected to be severe. Burden estimates based on RSV coding of hospital admissions are known to underestimate the burden of RSV. We aimed to provide robust and reliable age-specific burden estimates of RSV-associated hospital admissions based on data on respiratory infections from national health registers and laboratory-confirmed cases of RSV. Methods. We conducted multiseason regression analysis of weekly hospitalizations with respiratory infection and weekly laboratory-confirmed cases of RSV and influenza as covariates, based on national health registers and laboratory databases across 6 European countries. The burden of RSV-associated hospitalizations was estimated by age group, clinical diagnosis, and presence of underlying medical conditions. Results. Across the 6 European countries, hospitalizations of children with respiratory infections were clearly associated with RSV, with associated proportions ranging from 28% to 60% in children younger than 3 months and we found substantial proportions of admissions to hospital with respiratory infections associated with RSV in children younger than 3 years. Associated proportions were highest among hospitalizations with ICD-10 codes of “bronchitis and bronchiolitis.” In all 6 countries, annual incidence of RSV-associated hospitalizations was.40 per 1000 persons in the age group 0-2 months. In age group 1-2 years the incidence rate ranged from 1.3 to 10.5 hospitalizations per 1000. Adults older than 85 years had hospitalizations with respiratory infection associated to RSV in all 6 countries although incidence rates were low. Conclusions. Our findings highlight the substantial proportion of RSV infections among hospital admissions across different ages and may help public health professionals and policy makers when planning prevention and control strategies. In addition, our findings provide valuable insights for health care professionals attending to both children and adults presenting with symptoms of viral respiratory infections.
KW - burden of disease
KW - public health
KW - respiratory syncytial virus
KW - RSV
KW - time series analysis
KW - viral hospitalizations
UR - http://www.scopus.com/inward/record.url?scp=85141532278&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac150
DO - 10.1093/infdis/jiac150
M3 - Journal article
AN - SCOPUS:85141532278
SN - 0022-1899
VL - 226
SP - S29-S37
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -